Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $87.29, for a total value of $1,309,350.00. Following the sale, the chief executive officer directly owned 552,540 shares of the company’s stock, valued at $48,231,216.60. This trade represents a 2.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cameron Turtle also recently made the following trade(s):

• On Monday, August 3rd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $95.51, for a total value of $1,432,650.00.
• On Wednesday, July 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $87.69, for a total transaction of $1,315,350.00.

Spyre Therapeutics Price Performance

SYRE traded up $0.20 during trading on Thursday, reaching $87.25. 1,054,184 shares of the company’s stock were exchanged, compared to its average volume of 1,063,422. Spyre Therapeutics, Inc. has a 1 year low of $14.51 and a 1 year high of $110.18. The stock has a market capitalization of $7.67 billion, a P/E ratio of -44.74 and a beta of 2.99. The company’s fifty day simple moving average is $98.03 and its 200-day simple moving average is $74.53.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.40. Equities analysts forecast that Spyre Therapeutics, Inc. will post -2.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on SYRE. BTIG Research lowered their price target on shares of Spyre Therapeutics from $132.00 to $121.00 and set a “buy” rating on the stock in a report on Wednesday, August 26th. Wall Street Zen cut Spyre Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Guggenheim upped their target price on Spyre Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spyre Therapeutics in a report on Tuesday. Finally, Wolfe Research cut Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Spyre Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.69.

Institutional Trading of Spyre Therapeutics

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System raised its stake in shares of Spyre Therapeutics by 9,594.0% during the 2nd quarter. California State Teachers Retirement System now owns 5,742,912 shares of the company’s stock worth $509,856,000 after buying an additional 5,683,670 shares during the period. RTW Investments LP increased its holdings in Spyre Therapeutics by 15.2% in the 4th quarter. RTW Investments LP now owns 4,171,996 shares of the company’s stock worth $136,675,000 after acquiring an additional 550,000 shares in the last quarter. Vanguard Group Inc. raised its position in Spyre Therapeutics by 32.3% during the fourth quarter. Vanguard Group Inc. now owns 4,035,074 shares of the company’s stock worth $132,189,000 after acquiring an additional 984,344 shares during the period. Perceptive Advisors LLC raised its position in Spyre Therapeutics by 23.3% during the first quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company’s stock worth $190,826,000 after acquiring an additional 714,000 shares during the period. Finally, Capital International Investors lifted its holdings in Spyre Therapeutics by 46.0% during the fourth quarter. Capital International Investors now owns 3,492,541 shares of the company’s stock valued at $114,416,000 after purchasing an additional 1,100,000 shares in the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.